ERS International Congress 2023: highlights from the Thoracic Oncology Assembly

Abstract

Lung cancer is the leading cause of cancer mortality in the world. It greatly affects the patients’ quality of life, being a challenge for the daily practice in Respiratory Medicine. Advances in the genetic knowledge of thoracic tumours mutational landscape, the development of targeted therapies and immune checkpoint inhibitors, led to a paradigm shift in the treatment of lung cancer and pleural mesothelioma. During the annual ERS Congress in Milan, Italy, experts from all over the world presented their high-quality research and reviewed best clinical practices. Lung cancer screening, management of early-stages of lung cancer, application of artificial intelligence and biomarkers were discussed and they will be summarised here.